Richard Jordan named director of RTOG Biospecimen Resource
Richard C.K. Jordan, DDS, PhD, will direct the Radiation Therapy Oncology Group (RTOG) Biospecimen Resource housed at the University of California, San Francisco (UCSF).
Jordan is a professor of oral pathology, pathology and radiation oncology at UCSF and director of the Oral Pathology Diagnostic Laboratory and the UCSF Oral Cancer Tissue Bank. He also serves as the pathology chair for several RTOG clinical trials and has contributed to recent studies identifying the important role the human papilloma virus (HPV) plays in a subset of patients with head and neck cancer.
The focus of Jordan’s research is on precursors to oral cancer and head and neck cancer, with a particular interest in biomarkers of oral cancer development and prognosis. He has authored more than 100 research publications, book chapters and an oral pathology textbook worldwide.
Jordan assumes the directorship with the departure of Frederic Waldman, MD, PhD, who was instrumental in bringing the program to USCF in 2008.
As far as current goals for the program, Jordan said it will begin planning for RTOG’s alliance with the National Surgical Adjuvant Bowel and Breast Project.
Jordan is a professor of oral pathology, pathology and radiation oncology at UCSF and director of the Oral Pathology Diagnostic Laboratory and the UCSF Oral Cancer Tissue Bank. He also serves as the pathology chair for several RTOG clinical trials and has contributed to recent studies identifying the important role the human papilloma virus (HPV) plays in a subset of patients with head and neck cancer.
The focus of Jordan’s research is on precursors to oral cancer and head and neck cancer, with a particular interest in biomarkers of oral cancer development and prognosis. He has authored more than 100 research publications, book chapters and an oral pathology textbook worldwide.
Jordan assumes the directorship with the departure of Frederic Waldman, MD, PhD, who was instrumental in bringing the program to USCF in 2008.
As far as current goals for the program, Jordan said it will begin planning for RTOG’s alliance with the National Surgical Adjuvant Bowel and Breast Project.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.